



Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study

Yusi Chen¹, Jun Luo¹, Jingyuan Chen¹, Eugene Kotlyar², Zilu Li¹, Wenjie Chen¹ and Jiang Li^{1*}

¹Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Changsha, China, ²St. Vincent's Hospital, Sydney, NSW, Australia

Keywords: pulmonary arterial hypertension, macitentan, ambrisentan, endothelin receptor antagonist, real-word study

OPEN ACCESS

Edited and reviewed by:

Kevin Lu,
University of South Carolina,
United States

*Correspondence:

Jiang Li
lijiangcs@csu.edu.cn

Specialty section:

This article was submitted to
Drugs Outcomes Research and
Policies,
a section of the journal
Frontiers in Pharmacology

Received: 08 March 2022

Accepted: 15 March 2022

Published: 11 April 2022

Citation:

Chen Y, Luo J, Chen J, Kotlyar E, Li Z,
Chen W and Li J (2022) Corrigendum:
The Transition From Ambrisentan to
Macitentan in Patients With Pulmonary
Arterial Hypertension: A Real-Word
Prospective Study.
Front. Pharmacol. 13:891907.
doi: 10.3389/fphar.2022.891907

A Corrigendum on

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study

by Chen, Y., Luo, J., Chen, J., Kotlyar, E., Li, Z., Chen, W. and Li, J. (2022). *Front Pharmacol.* 12: 811700. doi:10.3389/fphar.2021.811700

In the original article, there was a mistake in **Table 1** and in the Section **Results, Patients' Clinical Characteristics** as published. "There were errors in the values for the 'Ambrisentan dose' as it was reported that one hundred and twenty-eight patients (88.3%) were receiving 10 mg once per day, whereas seventeen patients (11.7%) were receiving 5 mg once daily. This was corrected to sixty-one patients (42.1%) were receiving 10 mg once per day, and eighty-four patients (57.9%) were receiving 5 mg once daily." The corrected **Table 1** appears below and the text in the Section **Results, Patients' Clinical Characteristics** has been updated.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Luo, Chen, Kotlyar, Li, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

TABLE 1 | Baseline characteristics.

Characteristic	All patients (N = 145)
Age, years ^a	32.0 (26.0, 42.0)
Sex, n (%)	
Female	108 (74.5)
Male	37 (25.5)
Duration of ambrisentan treatment before transition, years ^a	1.5 (1.0, 2.9)
mPAP, mmHg ^{b,c}	61.4 ± 18.6
PVR, Wood ^{a,c}	14.4 (8.0, 22.1)
mRAP, mmHg ^{b,c}	10.0 ± 5.8
mRVP, mmHg ^{b,c}	41.7 ± 12.4
Etiology of PAH, n (%)	
Idiopathic	32 (22.1)
Drug or toxin-induced	4 (2.8)
Associated with connective tissue disease	21 (14.4)
Associated with congenital heart disease	88 (60.7)
Ambrisentan dose, mg, QD	
5 n (%)	84 (57.9)
10 n (%)	61 (42.1)
WHO FC, n (%)	
II	85 (58.6)
III	60 (41.4)
BMI (kg/m ²) ^b	21.0 ± 3.2
PAH medications in addition to taking ambrisentan, n (%)	
Monotherapy	18 (12.4)
PDE-5i	122 (84.1)
Riociguat	4 (2.8)
Riociguat and PDE-5i	1 (0.7)

^aData are described as medians and interquartile ranges (non-normal distribution).

^bData are described as means and standard deviations (normal or approximately normal distribution).

^cHistorical data from the most recent right heart catheterization before enrollment.

mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; mRAP, mean right atrial pressure; mRVP, mean right ventricular pressure; QD, once per day; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization functional class; BMI, body mass index; PDE-5i, phosphodiesterase type 5 inhibitor.